Evaxion Biotech A/S (EVAX)

Market Cap	15.12M
Revenue (ttm)	73,000
Net Income (ttm)	-22.13M
Shares Out	5.22M
EPS (ttm)	-8.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,441
Open	2.800
Previous Close	2.840
Day's Range	2.800 - 2.900
52-Week Range	2.260 - 13.820
Beta	-0.23
Analysts	Strong Buy
Price Target	11.00 (+279.97%)
Earnings Date	Aug 15, 2024

About EVAX

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: EVAX

Analyst Forecast

According to 2 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price forecast is $11.0, which is an increase of 279.97% from the latest price.

Price Target

$11.0

(279.97% upside)

Analyst Consensus: Strong Buy